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Abstract
Background. Darbepoetin alfa (DA) has been shown to be
an effective treatment of anaemia in patients with chronic
kidney disease (CKD) not on dialysis (NoD). EXTEND is
an observational study assessing the effectiveness of DA
administered once biweekly (Q2W) or monthly (QM) in a
general CKD-NoD population.
Methods. Adult CKD-NoD patients starting DA Q2W/QM
treatment in June 2006 or later were eligible. Retrospective
and/or prospective data including haemoglobin levels and
erythropoiesis-stimulating agent (ESA) dosing were col-
lected for 6 months before and 12 months after DA initia-
tion. Mean Hb levels were calculated every 3 months, and
ESA dose was converted to a geometric mean weekly DA
equivalent dose and summarized monthly.
Results. Data from 4278 patients showed that patients receiv-
ing ESAtreatment before DA Q2W/QM initiation had a mean
(95% conﬁdence interval) Hb level of 11.9 g/dL (11.8–12.0 g/
dL) at initiation and 11.6 g/dL (11.6–11.7 g/dL) at Months
10–12, with mean ESA dose of 22 lg/week (21–23 lg/week)
prior to initiation, 16 lg/week (15–16 lg/week) at initiation
and 16 lg/week (15–16 lg/week) at Month 12. In ESA-naive
patients, Hb levels increased from 10.3 g/dL (10.2–10.3 g/dL)
at initiation to 11.7 g/dL at Months 4–6 and were maintained
at a mean level of 11.7 g/dL (11.7–11.8 g/dL) at Months 10–
1 2 ,w i t hm e a nE S Ad o s eo f1 6lg/week (16–17 lg/week) at
initiation and 16 lg/week (16–17 lg/week) at Month 12. In
the 85% of patients receiving DA at extended intervals (Q2W
or less frequently) at Month 12, 12 patients (0.3%) experi-
enced DA-related adverse reactions.
Conclusion. DA Q2W/QM was an effective treatment of
anaemia in the general CKD-NoD patient population and
a dose increase was not required in patients switching from
a previous ESA regimen.
Keywords: anaemia; chronic kidney disease; darbepoetin alfa;
erythropoiesis-stimulating agent
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Erythropoiesis-stimulating agents (ESAs) improve and
maintain haemoglobin (Hb) levels in patients with anaemia
and chronic kidney disease (CKD) not on dialysis (NoD)
and reduce the need for red blood cell (RBC) transfusions
[1]. Recently, anaemia management strategies have ex-
plored extended dosing intervals with ESAs [2–5], possibly
allowing for more ﬂexible dosing, improving convenience
for patients and physicians and reducing waste (e.g. sy-
ringes) [6–8].
Studies in CKD-NoD patients have demonstrated the
efﬁcacy and safety of darbepoetin alfa (DA) administered
once biweekly (Q2W) or once monthly (QM) to partially
correct and/or maintain Hb levels [2–5, 9, 10]. However,
few studies have assessed the effectiveness of extended
dosing strategies in routine practice. Interpretation of re-
sults from trials in CKD-NoD patients is limited by patient
selection, whereas the general CKD-NoD population is a
spectrum of patients that differ by disease state and in-
cludes many with signiﬁcant comorbidities [11–13]. Fur-
thermore, renal anaemia management guidelines and ESA
labels have been changed over the last few years since
randomized controlled studies demonstrated no clinical
beneﬁt and even showed increased risk for some clinical
outcomes when treating CKD-NoD patients with ESAs to
high Hb targets (e.g. 13.5 g/dL) [14–19]. In Europe, the
recommended Hb target in ESA labels was decreased from
>11 g/dL (upper limit  14 g/dL) to a range of 10–12 g/dL
in 2008.
More data are needed to better characterize the CKD-
NoD population receiving ESA therapy. We describe the
interim analysis of EXTEND, an ongoing observational
study of CKD-NoD patients receiving DA subcutaneously
(SC) at extended dosing intervals (Q2W or QM) to treat
anaemia, with a primary objective of assessing the effec-
tiveness of DA Q2W/QM. The original protocol which
required follow-up of patients for up to 12 months after
DA initiation was amended to allow the follow-up of
patients for a longer period through disease progression,
including the need for dialysis.
Materials and methods
Study design and patients
EXTEND is a multicentre, longitudinal observational cohort study. Pa-
tients  18 years of age, NoD, with an estimated glomerular ﬁltration rate
(eGFR) of  59 mL/min/1.73m
2 (CKD Stages 3–5) were eligible if treat-
ment with DA Q2W/QM SC was initiated on June 2006 or later. Patients
were enrolled in Europe and Australia and treated according to local stand-
ard medical practice. Use of other ESA regimens (DA at other dosing
frequencies or other ESA types) prior to initiation of DA Q2W/QM was
allowed, butpatients enrolledin an interventional study6monthsbeforeor
at any time after initiation were ineligible. Procedures were followed in
accordance with the ethical standards of the responsible committee on
human experimentation (institutional and national) and with the Helsinki
Declaration of 1975, as revised in 2000.
Hb levels, ESA type, dose, frequency and route, relevant medical his-
tory, medications and laboratory measures were collected retrospectively
for up to 6 months prior to DA Q2W/QM initiation and retrospectively or
prospectively for up to 12 months after. Data on hospitalizations, DA-
related adverse drug reactions (ADRs) (as identiﬁed by the treating physi-
cian) and referral information were also collected. Primary end points were
achievement of Hb level >11 g/dL and absolute Hb level 12 months post-
initiation. The secondary end points were Hb concentrations over time,
anaemia practice patterns, patient characteristics and patient safety.
Statistical analysis
A sample size of 3500–4000 patients was estimated to ensure that the
primary end points could be calculated with sufﬁcient precision for sub-
groups of interest that represent the heterogeneity of the CKD-NoD pop-
ulation. Assuming an Hb SD of 1.4 g/dL, the 95% conﬁdence interval (CI)
widths for a subgroup that represented 5% of a study population of 3500
patients were estimated to be 14.8% for the proportion of patients with Hb
>11 and 0.41 g/dL for mean Hb level. For a study population of 4000
patients, the corresponding95% CIwidths wereestimated to be 13.8%and
0.39 g/dL, respectively.
Analyses are descriptive and, unless otherwise stated, were carried out
using the full analysis set (FAS) as observed and consisted of patients who
received at least one dose of DA Q2W/QM with no imputation for missing
data. For this interim analysis, the FAS as observed was restricted to
patients who had 12 months of data available or who withdrew from the
study and for whom all critical data queries relating to Hb and dose were
resolved at the time of analysis. Overall cohort data are presented and
subgroups stratiﬁed by prior ESA history—prior use of an ESA or non-
use (ESA naive) within 6 months of initiating DA Q2W/QM. Mean Hb
levels were calculated for 3-month intervals. ESA dose was calculated for
1-month intervals and normalized to a geometric mean (log transforma-
tion) weekly equivalent due to the impact of non-normal data distribution
on the arithmetic mean. Epoetin alfa/beta doses were converted from IU to
lg using the conversion factor 200 IU:1 lg per the DA label. To explore
the sensitivity of the primary analysis of the primary end points to missing
data, a predeﬁned sensitivity analysis of primary end points also used the
FAS with the last observation carried forward (LOCF), in which missing
Hb data in a 3-month window were replaced with the previously available
3-month Hb values (with no imputation from pre-initiation to post-
initiation).
The study sponsor conducted all statistical analyses with SAS/STAT
software (version 8.2; SAS Institute Inc., Carey, NC). Authors had access
to all clinical data outputs and were fully involved in formulating the
analyses and questions of interest.
Results
The FAS comprised 4278 patients enrolled at 342 centres
in 18 European countries and Australia. Due to outstanding
critical data queries relating to Hb and ESA dose, 148
patients were not included in the analysis. Extended dosing
with DA was initiated at Q2W for 3749 patients (88%) and
at QM for 527 (12%) patients; dose frequency data were
missing for 2 patients. Twelve months of data were avail-
able for 2836 patients (66%),  9t o<12 months of data
were available for 1151 patients (27%) and <9 months of
data were available for 291 patients (7%). Reasons for
dropout were patient no longer treated at clinic, consent
withdrawal, kidney transplant, death and other reasons
not categorized. Protocol violations included initiation of
DA Q2W before June 2006 (36 patients), initiation of DA
at Q2W or less frequently prior to the recorded initiation
date (95 patients) and Stage 1 or 2 CKD (30 patients).
Table 1 summarizes patient characteristics at initiation of
extended dosing. The mean ( SD) patient age was 67.4
( 15.0) years. Most patients (51%) enrolled were in Stage
4 CKD, and 19% of patients enrolled were in Stage 5 CKD.
Common CKD aetiologies were diabetes mellitus (25%)
and hypertension (24%). The prevalence of type 2 diabetes
mellitus was 32% and cardiovascular disease was 58%.
ESAs were used previously by 48.7% of patients, while
51.3% were ESA naive. Patients in both subgroups had
similar characteristics.
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ESA dose data for the two subgroups are presented in
Figure 1. In the prior ESA subgroup, mean Hb increased
before initiation and continued to increase immediately
after initiation, then decreased and stabilized at around
the 7- to 9-month interval. The proportion of patients with
Hb levels >11 g/dL was 1288/1802 (71%) at initiation and
1307/1865 (70%) for Months 10–12. Increasing Hb levels
corresponded to a reduction in the geometric mean weekly
ESA dose at initiation compared with pre-initiation dosing
with no dose penalty in the post-initiation period.
In the ESA-naive subgroup, the mean Hb level decreased
before initiation, increased after initiation, then stabilized
aroundthe 7-to9-month period. The post-initiation Hb level
increase resulted in an increase in the proportion of patients
with Hb levels >11 g/dL from 342/1842 (19%) at initiation
to 1359/1885 (72%) for Months 10–12. After initiation, the
geometric mean weekly ESA dose was stable.
In the FAS population, the mean Hb for Months 10–12
was 11.67 g/dL (95% CI, 11.63–11.71 g/dL) with a geo-
metric mean weekly dose of 15.9 lg (95% CI, 15.5–16.3
lg). Haemoglobin levels were >11 g/dL in 2666/3750
(71%) of patients for Months 10–12. Haemoglobin data
from the FAS-LOCF sensitivity analysis were comparable
to the primary analysis with no imputation with a mean Hb
level of 11.64 g/dL (95% CI, 11.60–11.68 g/dL) for
Months 10–12 with 2945/4221 (70%) of patients having
Hb levels >11 g/dL. Overall, 93% of patients remained in
the study beyond 9 months and 11% of data were imputed
in the LOCF analysis.
Results were generally consistent across countries,
although differences were observed for mean Hb levels at
initiation and geometric mean weekly ESA dose. The anal-
ysis by country was limited by small sample sizes.
Anaemia treatment patterns
Before initiation of DA Q2W/QM, most patients (70%) in
the prior ESA subgroup had been receiving DA QW, 8%
had been receiving DA at other dosing intervals and 18 and
3% had been receiving epoetin beta and alfa, respectively.
After initiation, some patients required modiﬁcation to the
ESA dosing regimen (Table 2). For Months 7–12, 43% of
Table 1. Patient characteristics at initiation of DA Q2W/QM
a,b
Overall (N ¼ 4278) Prior ESA (n ¼ 2085) ESA naive (n ¼ 2193)
Age, mean (6SD), years 67.4 (615.0) 66.6 (615.2) 68.2 (614.8)
Sex
Female 2066 (48) 1018 (49) 1048 (48)
Male 2208 (52) 1066 (51) 1142 (52)
Unknown 4 (<1) 1 (<1) 3 (<1)
Race/ethnicity
White 3221 (75) 1586 (76) 1635 (75)
Black 16 (<1) 9 (<1) 7 (<1)
Asian 46 (1) 23 (1) 23 (1)
Other 28 (1) 18 (1) 10 (<1)
Unknown 967 (23) 449 (22) 518 (24)
CKD stage
Stage 1
c 2( <1) 1 (<1) 1 (<1)
Stage 2
c 28 (1) 13 (1) 15 (1)
Stage 3 1082 (25) 530 (25) 552 (25)
Stage 4 2203 (51) 1056 (51) 1147 (52)
Stage 5 819 (19) 423 (20) 396 (18)
Missing 144 (3) 62 (3) 82 (4)
Primary aetiology of CKD
Hypertension 1023 (24) 450 (22) 573 (26)
Glomerulonephritis 561 (13) 309 (15) 252 (11)
Diabetes mellitus 1055 (25) 502 (24) 553 (25)
Interstitial nephropathy/obstructive nephropathy 397 (9) 211 (10) 186 (8)
Tumours 41 (1) 20 (1) 21 (1)
Polycystic kidney/hereditary disease 217 (5) 105 (5) 112 (5)
Unknown aetiology 461 (11) 235 (11) 226 (10)
Other 523 (12) 253 (12) 270 (12)
Prior history of diabetes
Type I 209 (5) 101 (5) 108 (5)
Type II 1385 (32) 672 (32) 713 (33)
Unknown type 27 (1) 10 (<1) 17 (1)
No history 2600 (61) 1277 (61) 1323 (60)
Unknown 57 (1) 25 (1) 32 (1)
Prior history of cardiovascular disease
Yes 2477 (58) 1158 (56) 1319 (60)
No 1683 (39) 869 (42) 814 (37)
Unknown 118 (3) 58 (3) 60 (3)
Haemoglobin, mean (6SD), g/dL 11.08 (1.57) 11.90 (1.57) 10.29 (1.10)
aQ2W, once every 2 weeks; QM, once monthly.
bNumber of patients (%) unless noted otherwise.
cProtocol violations.
Extended dosing of DA 2305patients in the prior ESA subgroup required 1–2 dose
changes, 28% required 1–2 dose frequency changes, while
52% required no modiﬁcations. Similar dose modiﬁcation
requirements were observed in the ESA-naive subgroup
during the post-initiation period. Dosing data at 12 months
from 3595 patients showed the following DA frequencies:
51% Q2W, 28% QM, 11% QW, 5% once tri-weekly and
2% at other frequencies. About 3% had switched to other
ESA types. Route of administration was SC for 95% of
patients and intravenously for 5%.
WithinthepriorESAsubgroup,ironuserangedfrom42to
46%ofpatientsthroughoutthestudy(Figure2),whereasiron
use in the ESA-naive subgroup increased from pre-initiation
(range, 21–30%) to post-initiation (range, 44–45%). Trans-
ferrin saturation and serum ferritin levels, from a limited
number of patients, remained satisfactory in both subgroups;
although decreases were observed for the 3-month average
before initiation in the prior-ESA subgroup with mean levels
of 21.7% and 199 lg/L, respectively, and for the 3-month
averageafterinitiationintheESA-naivesubgroupwithmean
levels of 21.8% and 194 lg/L, respectively.
RBC transfusions were infrequent in both subgroups
(Figure 3). In the prior ESA subgroup, the tri-monthly
transfusion rate ranged from 2to 4%. There was an increase
in RBC transfusions pre-initiation in the ESA-naive sub-
group, from 3% (Months  6t o 4) to 6% (Month  3t o
initiation). Post-initiation, the tri-monthly transfusion rate
ranged from 1 to 3%.
Fig. 1. Haemoglobin and ESA dose. Mean haemoglobin and geometric mean weekly equivalent ESA dose before and after initiation of DA Q2W/QM in
the (A) prior ESA subgroup and (B) ESA-naive subgroup. Error bars represent the 95% CI. [I], initiation of DA Q2W/QM; P, immediately prior to
initiation. *Hb level deﬁned as single closest value 645-day analysis time window except at initiation (–8-week analysis time window) and Months 10–
12 (–90 to 120 day time window); no imputation for missing data.
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DA-related ADRs were reported in 12 patients and in-
cluded 17 different preferred terms as follows: dizziness,
headache (x2), hypersensitivity, hypertension (x4), inﬂu-
enza, leukopoenia, malaise, puncture site reaction, phlebi-
tis, rash (x2), tachycardia and vertigo. Serious ADRs were
pancreatic carcinoma and subdural haematoma (one patient
for each), with no causal relationship established. There
were no reports of antibody-mediated pure RBC aplasia.
Hospitalizations
Post-initiation, 1346/4278 (31%) patients were hospital-
ized, with a tri-monthly hospitalization rate ranging from
10 to 12% (Table 3), and an infrequent admission to the
intensive care unit. Reasons for hospitalization included
planned surgery and infection. The tri-monthly incidence
of hospitalization for stroke remained <1%.
Renal replacement therapy
The mean eGFR declined during the pre- but not the post-
initiation periods. Mean eGFR, excluding patients who had
a signiﬁcant eGFR decline and progressed to dialysis, was
26 mL/min/1.73m
2 (95% CI, 25 26 mL/min/1.73m
2) for
Month  6, 24 mL/min/1.73m
2 (95% CI, 24 25 mL/min/
1.73m
2) at initiation and 24 mL/min/1.73m
2 (95% CI,
23 24 mL/min/1.73m
2) for Month 12 (Figure 4). How-
ever, the rate of starting renal replacement therapy (RRT)
post-initiation was stable, ranging from 3.5 to 3.7% per
3-month interval. During the 12 months after initiation, a
total of 598 patients (14.1%) started RRT with rates of
2.1% (23/1082), 9.9% (219/2203) and 41.3% (338/819)
for CKD Stages 3, 4 and 5, respectively.
Treatment discontinuations
During the 12-month post-initiation period, 368 patients
(9%) discontinued ESA treatment due to death [157 pa-
tients (4%)], kidney transplant [17 patients (1%)] or other
reasons [192 patients (4%)]; no reason was speciﬁed for 2
patients (<1%).
Discussion
Interim analysis of the EXTEND observational study indi-
cates that treatment of CKD-NoD patients with DA Q2W/
QM was effective for the partial correction and/or mainte-
nance of Hb levels, with no indication of safety issues.
Mean Hb levels were maintained in the prior ESA sub-
group and were corrected and maintained in the ESA-naive
subgroup. Both the DA Q2W and QM regimens were well
tolerated as DA-related ADRs were infrequent, but data
limitations preclude any deﬁnitive interpretation. Changes
to ESA dose and dose frequency were required for some
patients. Most patients were receiving DA Q2W/QM at
Month 12, with a doubling in the proportion of patients
receiving DA QM (from 12 to 28%), which may reﬂect
patients initiating DA Q2W then switching to QM dosing.
Some patients switched to different ESA regimens.
Despite the limitations of observational data, some
trends in this analysis are noteworthy. In the prior ESA
subgroup, the increasing Hb levels prior to initiation and
the corresponding drop in ESA dose at initiation likely
reﬂect a common practice among nephrologists in Europe
to initiate extended dosing with ESA in order to modify the
total ESA dose, particularly in patients who demonstrate
a good response to initial ESA treatment. Most patients
were receiving DA QW prior to initiation and initiated
extended dosing with DA at the Q2W frequency. Changes
to both the dose and dose frequency were observed after
initiation and illustrate the use of ﬂexible dosing by clini-
cians. Maintaining stable Hb levels in CKD patients can be
challenging as a number of patient-related factors and in-
tercurrent events such as hospitalizations [20–22] may af-
fect Hb stability [13, 20, 23, 24].
DA Q2W/QM initiation was associated with a decrease in
RBC transfusion requirements in the ESA-naive subgroup.
The highest transfusion rate in this subgroup corresponded
toa trend ofdecreasingHblevelsin the pre-initiation period.
The tri-monthly transfusion rate in the 3 months prior to
initiation was 6% compared with a lower rate of 3% in the
ﬁrst 3 months after initiation. While a causal relationship
cannot be established in an observational study, these data
are consistent with the literature [1, 18, 25].
Table 2. Post-initiation dose and dose frequency changes after initiation of DA Q2W/QM
a
Prior ESA ESA naive
1–6 months (n ¼ 2085) 7–12 months (n ¼ 1983) 1–6 months (n ¼ 2193) 7–12 months (n ¼ 2048)
Injection dose or frequency changes, n (%)
No changes 1066 (51) 1032 (52) 1055 (48) 1069 (52)
1–2 changes 900 (43) 865 (44) 1041 (47) 868 (42)
 3 changes 119 (6) 86 (4) 97 (4) 111 (5)
Injection dose changes, n (%)
No changes 1094 (52) 1043 (53) 1082 (49) 1089 (53)
1–2 changes 879 (42) 858 (43) 1018 (46) 856 (42)
 3 changes 112 (5) 82 (4) 93 (4) 103 (5)
Frequency changes, n (%)
No changes 1457 (70) 1400 (71) 1485 (68) 1484 (72)
1–2 changes 599 (29) 558 (28) 685 (31) 534 (26)
 3 changes 29 (1) 25 (1) 23 (1) 30 (1)
aQ2W, once every 2 weeks; QM, once monthly.
Extended dosing of DA 2307The types of DA-related ADRs reported were consistent
with those in the literature [2, 5, 18]. The low ADR rates
suggest that treatment was well tolerated, but this may also
be related to under-reporting [26]. Although some studies
have indicated an increased risk of pancreatic carcinoma
with ESA treatment in certain cancer patients [27], such
a relationship cannot be established with the current data.
During the post-initiation period, 14% of patients started
RRT, 31% were hospitalized and 4% died (based on reason
for discontinuing ESA treatment). These outcomes appear to
be consistent with other observational studies in CKD-NoD
populations. However, EXTEND was not designed as an
outcomes study. Moreover, deﬁnitive comparisons cannot
be made because of differences in study design and patient
populations [28–33]. In this interim analysis, hospitalization
and mortality data did not go beyond the 12-month post-
initiation period, were not captured in a systematic manner
that allows in-depth analysis and lacked detail.
Nevertheless, mortality and morbidity data obtained
from this study are of clinical interest, particularly in view
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Fig. 2. Iron therapy and iron parameters. Patients receiving iron therapy in tri-monthly intervals before and after the initiation of DA Q2W/QM in the (A)
prior ESA and (B) ESA-naive subgroups and the mean levels for transferrin saturation and serum ferritin. *Denominator does not include patients with
missing data. [I], initiation of DA Q2W/QM; TSAT, transferrin saturation.
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comes in Renal Insufﬁciency (CHOIR) trial and the Trial to
Reduce Cardiovascular Events with Aranesp Therapy
(TREAT). In both trials, ESA treatment to high Hb targets
was linked with adverse outcomes [15, 18].
In CHOIR, CKD-NoD patients (Stage 3/4) were
randomized to achieve an Hb target of 13.5 versus 11.3
g/dL with epoetin alfa treatment and followed for 3 years.
Compared with patients in the low Hb target arm, patients
in the high Hb target arm were at greater risk for the pri-
mary composite outcome of death, myocardial infarction,
hospitalization for congestive heart failure and stroke [haz-
ard ratio (HR), 1.34; 95% CI, 1.03–1.74] [15]. There was
no signiﬁcant difference between treatment arms for death
from any cause (7.3 versus 5.0%, respectively; P ¼ 0.07),
incidence of stroke (1.7% in each arm) or RRT (21.7 versus
18.7%, respectively; P ¼ 0.15).
In TREAT, diabetic CKD-NoD (Stage 3/4) patients were
randomized to receive DA treatment to achieve an Hb tar-
get of 13 g/dL versus a placebo control with rescue DA if
the Hb was <9 g/dL and a return to placebo after Hb was
 9 g/dL. Patients were followed for up to 48 months.
While there was no difference between treatment arms
for the primary cardiovascular composite and renal compo-
site end points, a signiﬁcant increase in the incidence of
stroke was seen in the interventional arm compared with
the control arm (5 versus 2.6%; HR, 1.92; 95% CI, 1.38–
2.68). Death from any cause did not differ between the
treatment arms (20.5 versus 19.5%, respectively; P ¼
0.48) nor did progression to end-stage renal disease (16.8
versus 16.3%, respectively; P ¼ 0.83).
Although of clinical interest, any comparison of morbid-
ity and mortality data of EXTEND to these randomized
controlled trials must be qualiﬁed. Observational and clin-
ical trial data in patients with renal anaemia have not corre-
lated well [34], and there are important differences in the
treatment goals of these studies. EXTEND was a non-
interventional study with patients treated according to the
standards of the participating centres, including those for
Hb targets, rather than the restrictions set by the protocol of
an interventional study.
While conclusions from comparisons of the outcomes
data are limited, it is noteworthy that ESA dosing appeared
to be much lower in EXTEND than in both CHOIR and
TREAT. For 3501 patients receiving DA (any dosing
schedule) at 12 months in EXTEND, the geometric mean
weekly dose was 15.7 lg, arithmetic mean weekly dose
was 21.1 lg and the median was 15.0 lg. The mean weekly
epoetin alfa dose in the CHOIR study was 11 215 IU (~56
lg) in the high Hb target arm and 6276 IU (~31 lg) in the
low Hb target arm [15]. During TREAT, the median
monthly dose was 176 lg( ~41 lg/week) in the
Table 3. Hospitalizations after initiation of DA Q2W/QM for the overall cohort (N ¼ 4278)
a
Months after initiation
1 3( n ¼ 4299) 4 6( n ¼ 4161) 7 9( n ¼ 4084) 10 12 (n ¼ 3992)
Patients hospitalized, n (%) 509 (12) 477 (11) 496 (12) 441 (11)
Admitted to ICU
b 29 (6) 40 (8) 43 (9) 40 (9)
No. of hospitalizations 618 589 608 537
Primary reason, n (%)
Ischaemic heart disease 21 (<1) 28 (1) 29 (1) 23 (1)
Peripheral vascular disease 19 (<1) 16 (<1) 14 (<1) 10 (<1)
Hyperkalaemia 8 (<1) 7 (<1) 4 (<1) 1 (<1)
Infection 82 (2) 75 (2) 106 (2) 76 (2)
Congestive heart failure 17 (<1) 22 (1) 19 (<1) 19 (<1)
Arrhythmia 9 (<1) 3 (<1) 9 (<1) 11 (<1)
Stroke 4 (<1) 8 (<1) 4 (<1) 10 (<1)
Haemorrhage 19 (<1) 18 (<1) 18 (<1) 18 (<1)
Convulsions 2 (<1) 1 (<1) 3 (<1) 0 (0)
Fractures 12 (<1) 7 (<1) 10 (<1) 9 (<1)
Electrolyte disorders 15 (<1) 12 (<1) 23 (1) 15 (<1)
Planned surgery 107 (3) 126 (3) 110 (3) 106 (2)
Others 230 (5) 209 (5) 202 (5) 187 (4)
Unknown 2 (<1) 2 (<1) 1 (<1) 3 (<1)
Duration, median (Q1, Q3) 6.0 (3.0, 11.0) 7.0 (3.0, 13.0) 7.0 (3.0, 12.0) 7.0 (4.0, 13.5)
aICU, intensive care unit; Q1 lower quartile; Q3, upper quartile; Q2W, once every 2 weeks; QM, once monthly.
bDenominator is number of patients hospitalized.
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Fig. 3. RBC transfusions. Transfusions before and after the initiation of
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Extended dosing of DA 2309interventional arm and 0 lg in the placebo arm [18].
Although we have no deﬁnitive explanation for this dis-
crepancy, it may be indicative of a lower comorbidity level
and less ESA resistance in the EXTEND patients.
Other limitations of this study are acknowledged, includ-
ing confounding by indication for subgroup comparisons
and selection criteria for patients. Patients were required to
have initiated DA Q2W/QM at one of the participating
centres, which limits the generalizability of the data. For
example, the increasing Hb levels in the prior ESA sub-
group pre-initiation and low dosing requirements post-ini-
tiation is likely to reﬂect a population of patients who were
responding well to ESA treatment. Also, important regu-
latory changes occurred during the course of the study in
2008 that altered the Hb target for patients with renal anae-
mia, which may have confounded data. Analyses of the
potential impact of the regulatory and guidelines changes
on clinical practice patterns will be considered in subse-
quent reports of EXTEND.
The design of the study allowed for a mixture of retro-
spective and prospective data to be collected for each sub-
ject and allowed the amount of retrospective data to vary
among subjects. To assess the possible impact of this, a
sensitivity analysis was conducted by splitting subjects into
subgroups according to when they enrolled relative to the
observation period, but this analysis was confounded by
time. Subjects with a large amount of retrospective data
tended to have been enrolled early in the study when the
higher Hb targets were in place, whereas subjects with few
retrospective data were generally enrolled later, when
lower Hb targets were in place. The distribution of the
number of Hb values per subject was explored, and no
differences were found between the time periods when data
were collected retrospectively and prospectively.
Missing data can also be a limitation of observational
studies. Missing Hb data at a particular time point may be
attributable to subjects having withdrawn from the study or
to a lack of available Hb values in the 3-month time win-
dow (because of the observational nature of the data col-
lection). The number of subjects providing Hb data at each
time point is shown in Figure 1 and was fairly stable over
time. The overall dropout rate during the 12 months of the
study was low, and 3987 (93%) of subjects in this analysis
contributed at least 9 months of data post-DA Q2W/QM
initiation. A sensitivity analysis of the primary end points
imputed 11% of data using the LOCF method, and the
results were consistent with the primary analysis.
Despitetheselimitations,EXTENDprovidesvaluabledata
for a large CKD-NoD population in routine practice. Sub-
group analyses are planned, and long-term follow-up will
providemoredataontransitiontodialysis.Thisisparticularly
relevantinviewoftheresultsfromthe3-yearCardiovascular
Risk Reduction by Early Anaemia Treatment with Epoetin
Beta (CREATE) trial, which assessed the safety and efﬁcacy
of treating CKD-NoD (eGFR 15–35 mL/min/1.73m
2)p a -
tients to an Hb target of 13–15 g/dL with epoetin beta versus
a target of 10.5–11.5 g/dL [14]. Although there was no sig-
niﬁcantdifferencebetweenthetreatmentarmsfortheprimary
compositeendpointofcardiovascularevents,timetodialysis
was signiﬁcantly shorter in the high Hb target group
(P ¼ 0.03) with a median weekly ESA dose of 5000 IU
(~25lg). AdditionalanalysesofEXTEND willprovide data
n 3316 3550 4134 3954 3925 3818 3749
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